Disruptive Healthcare: CEO video series - John Dawson, Oxford Biomedica
Oxford Biomedica is a £xxxm market cap company and the world’s leading expert in the design and manufacture of lentiviral vectors for gene therapy. In this video, CEO John Dawson discuss the evolving landscape for lentiviral vector demand, the recent signing of a major deal with Juno, its ability to meet this anticipated increase in demand and lastly its important involvement in the Oxford University/AstraZeneca COVID-19 vaccine.
*The views in these video are of Oxford BioMedica CEO John Dawson, CEO of Diaceutics, Peter Keeling and Stuart Quin Medica group CEO.
This communication is for use only by a person or entity that qualifies as a "Professional Client" or "Eligible Counterparty" within the meaning of the FCA's rules. It is intended for use only by persons having professional experience in matters relating to investments. Any other person who receives this should not act on the contents. Disclaimer here